We are a life science innovation center that supports health tech entrepreneurs providing strategic mentorship and resources, experts and office space for growth.

THE MISSION

To accompany health tech startups to their next significant valuation milestones.

 

view more

OFFERS

Neighborhood offers tailed in-residence mentoring, coaching and global access to health tech entrepreneurs.

 

view more

COMMUNITY

Last events

meetings

How to obtain a market approval for a health tech application or a software?

Thursday October 4, 2018 - 18 h 00 min-21 h 00 min
Agenda 18 h-18 h 30: Welcome 18 h 30-19 h: Presentation from David Sainati, Founder & President ...
Add to Calendar

HOW TO APPLY

Tell us about your idea, technology, or innovation and how we can work together to empower you to reach your next milestone in product development.

 

Join usI have a question

Would like to learn more
on our programs or take a tour?

op2 lysis

THERAPEUTIC AREA
Cardiology, neurology, stroke
LOCATION COUNTRY
Paris, France

WEBSITE
https://www.op2lysis.com

OP2lysis

Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide. Op2lysis program aims at validating the clinical safety and the efficacy of its therapeutic solution to be ready to enter advanced phases of development by 2022. Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of lytic treatment in stroke, the first cause of acquired handicap worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.

op2 lysis

THERAPEUTIC AREA
Cardiology, neurology, stroke
LOCATION COUNTRY
Paris, France

WEBSITE
https://www.op2lysis.com

OP2lysis

Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide. Op2lysis program aims at validating the clinical safety and the efficacy of its therapeutic solution to be ready to enter advanced phases of development by 2022. Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of lytic treatment in stroke, the first cause of acquired handicap worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.

op2 lysis

THERAPEUTIC AREA
Cardiology, neurology, stroke
LOCATION COUNTRY
Paris, France

WEBSITE
https://www.op2lysis.com

OP2lysis

Op2Lysis develops the first treatment for hemorrhagic stroke a life-threatening disease that affects >1,5M people every year worldwide. Op2lysis program aims at validating the clinical safety and the efficacy of its therapeutic solution to be ready to enter advanced phases of development by 2022. Op2Lysis is a biotech company dedicated to the development of innovative products to improve the benefit of lytic treatment in stroke, the first cause of acquired handicap worldwide. Christophe GAUDIN and Jérôme PARCQ are the co-founders of Op2Lysis, which benefits from their complementary experiences and skills.

op2 innovative drug

THERAPEUTIC AREA
Cardiology

LOCATION COUNTRY
Pessac, France

 

OP2 Innovative Drugs

OP2 Drugs SAS ("OP2") is a biotech company that aims at developing innovative life-saving drugs for unmet medical needs, especially in the cardiology field. Our first patented compound, OP2113, which targets mitochondrial dysfunction, is in the preclinical stage, with a strong scientific rationale. Based on strategic partnerships in Europe and in the US, we are generating growth and value for all stakeholders thanks to our drug candidates pipeline, in several indications. OP2 is planned to move forward to clinical in 2018. Located in Pessac, close to Bordeaux (France), OP2 Drugs is supported by Unitec (Bordeaux), managed by Frédéric Marin (CEO) and Nicolas Pineau (COO), and funded by ambitious financial players.

man ros therapeutics

THERAPEUTIC AREA
Cystic Fibrosis, Polycystic kidney disease, neurodegenerative diseases.
LOCATION COUNTRY
Roscoff, France

WEBSITE
www.manros-therapeutics.com/

MANROS THERAPEUTICS

ManRos Therapeutics develops novel drug candidates acting against severe pathologies, namely cystic fibrosis, neurodegenerative disorders (Alzheimer’s disease and Down syndrome), and some renal diseases (including polycystic kidney disease). Anomalies in phosphorylation are observed in the three pathologies on which ManRos Therapeutics carries out its research: they share common targets and similar mechanisms.

My vision

THERAPEUTIC AREA
Ophthalmology
LOCATION COUNTRY
Paris, France

 

aiVision

aiVision est une solution innovante d’aide au diagnostic à distance en téléophtalmologie basée sur des algorithmes d’intelligence artificielle. Grâce à la science des données issue de l’apprentissage de centaine de milliers de clichés de fonds d’œil, l’ophtalmologiste accélère son diagnostic en validant le score proposé par des algorithmes spécialement entrainés à dépister précocement les principales maladies de la vision sur clichés digitaux de fonds d’œil pris à distance par des professionnels de santé. La solution est déjà en en cours de déploiement auprès de services d’endocrinologie de certains hôpitaux publics et privés en France et bénéficie d’une prise en charge par l’Assurance Maladie. A l’étranger, notre solution est souvent également financée par payeurs privés (assureurs, mutuelles aux USA-CAN, Moyen-Orient).